Azhar Khandekar

Azhar Khandekar

Auto-generated profile, based on publicly available information

Azhar Khandekar

National Cancer Institute 1 Division of Cancer Epidemiology and Genetics Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CSChristopher D. Steele
Christopher D. Steele
AAAmmal Abbasi
Ammal Abbasi
SIS M Ashiqul Islam
S M Ashiqul Islam
AKAzhar Khandekar
Azhar Khandekar
KHKerstin Haase
Kerstin Haase
NPNischalan Pillay
Nischalan Pillay
The gains and losses of DNA that emerge as a consequence of mitotic errors and chromosomal instability are prevalent in cancer. These copy number alterations contribute to cancer initiaition, progression and therapeutic resistance. Here, we present a conceptual framework for examining the patterns of copy number alterations in human cancer using whole-genome sequencing, whole-exome sequencing, and SNP6 microarray data making it widely applicable to diverse datasets. Deploying this framework to 9,873 cancers representing 33 human cancer types from the TCGA project revealed a set of 19 copy number signatures that explain the copy number patterns of 93% of TCGA samples. 15 copy number signatures were attributed to biological processes of whole-genome doubling, aneuploidy, loss of heterozygosity, homologous recombination deficiency, and chromothripsis. The aetiology of four copy number signatures are unexplained and some cancer types have unique patterns of amplicon signatures associated with extrachromosomal DNA, disease-specific survival, and gains of proto-oncogenes such as MDM2 . In contrast to base-scale mutational signatures, no copy number signature associated with known cancer risk factors. The results provide a foundation for exploring patterns of copy number changes in cancer genomes and synthesise the global landscape of copy number alterations in human cancer by revealing a diversity of mutational processes giving rise to copy number changes.

6 May 2025 in Cancer Research
Verified
Journal Article
Open access
AAAmmal Abbasi
Ammal Abbasi
CSChristopher D. Steele
Christopher D. Steele
EBErik N. Bergstrom
Erik N. Bergstrom
AKAzhar Khandekar
Azhar Khandekar
AFAkanksha Farswan
Akanksha Farswan
LALudmil B. Alexandrov
Ludmil B. Alexandrov
Breast and ovarian cancers harboring homologous recombination deficiency (HRD) are sensitive to PARP inhibitors and platinum chemotherapy. Conventionally, detecting HRD involves screening for defects in BRCA1, BRCA2, and other relevant genes. Recent analyses have shown that HRD cancers exhibit characteristic mutational signatures due to the activities of HRD-associated mutational processes. At least three machine learning tools exist for detecting HRD based on mutational patterns. In this study, using sequencing data from 1,043 breast and 182 ovarian cancers, we trained Homologous Recombination Proficiency Profiler (HRProfiler), a machine learning method for detecting HRD using six mutational features. The performance of HRProfiler was assessed against prior approaches using additional independent datasets of 417 breast and 115 ovarian cancers, including retrospective data from a clinical trial involving patients treated with PARP inhibitors. Individual HRD-associated mutational signatures alone did not consistently detect HRD or predict clinical response across datasets. Notably, while all tools performed comparably for whole-genome–sequenced cancers, HRProfiler was the only approach that consistently identified HRD in whole-exome–sequenced breast and ovarian cancers, offering clinically relevant insights. Retrospective analyses provided strong evidence that HRProfiler could serve as a valuable tool for predicting HRD and clinical response in breast and ovarian cancers. This study provides the rationale for large-scale prospective clinical trials to validate the potential of HRProfiler as a routine predictive and/or prognostic HRD biomarker to guide clinical decision-making. Significance: HRProfiler is a machine learning approach that reliably identifies homologous recombination deficiency in whole-exome–sequenced breast and ovarian cancers, outperforming other tools and providing clinically useful insights. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI. See related commentary by Lim and Ju, p. 2348

30 October 2025 in Cancer Discovery
Verified
Journal Article
Closed access
WZWei Zhao
Wei Zhao
TZTongwu Zhang
Tongwu Zhang
XHXing Hua
Xing Hua
PHPhuc Huu Hoang
Phuc Huu Hoang
MMMona Miraftab
Mona Miraftab
MLMaria Teresa Landi
Maria Teresa Landi
Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA sequencing data from 684 NS-LUAD cases and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histologic data further characterized the subtypes. “Steady,” marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver gene alterations, is linked to prolonged survival and low immune evasion. “Proliferative” shows high proliferation markers, TP53 mutations, and gene fusions. “Chaotic,” with high epithelial-to-mesenchymal transition markers, has the worst prognosis, even within stage I tumors. Lacking known molecular or histologic characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings. Significance: The transcriptome of 684 NS-LUAD identifies three subtypes with different cellular dynamics and genomic and morphologic features. A 60-gene signature accurately stratifies subjects for mortality risk, even in stage I, offering a potential clinically applicable tool for treatment decision-making in patients with NS-LUAD. See related commentary by Azizi et al., p. 423

2 July 2025
Verified
Other
Open access
AAAmmal Abbasi
Ammal Abbasi
CSChristopher D. Steele
Christopher D. Steele
EBErik N. Bergstrom
Erik N. Bergstrom
AKAzhar Khandekar
Azhar Khandekar
AFAkanksha Farswan
Akanksha Farswan
LALudmil B. Alexandrov
Ludmil B. Alexandrov
Breast and ovarian cancers harboring homologous recombination deficiency (HRD) are sensitive to PARP inhibitors and platinum chemotherapy. Conventionally, detecting HRD involves screening for defects in BRCA1, BRCA2, and other relevant genes. Recent analyses have shown that HRD cancers exhibit characteristic mutational signatures due to the activities of HRD-associated mutational processes. At least three machine learning tools exist for detecting HRD based on mutational patterns. In this study, using sequencing data from 1,043 breast and 182 ovarian cancers, we trained Homologous Recombination Proficiency Profiler (HRProfiler), a machine learning method for detecting HRD using six mutational features. The performance of HRProfiler was assessed against prior approaches using additional independent datasets of 417 breast and 115 ovarian cancers, including retrospective data from a clinical trial involving patients treated with PARP inhibitors. Individual HRD-associated mutational signatures alone did not consistently detect HRD or predict clinical response across datasets. Notably, while all tools performed comparably for whole-genome–sequenced cancers, HRProfiler was the only approach that consistently identified HRD in whole-exome–sequenced breast and ovarian cancers, offering clinically relevant insights. Retrospective analyses provided strong evidence that HRProfiler could serve as a valuable tool for predicting HRD and clinical response in breast and ovarian cancers. This study provides the rationale for large-scale prospective clinical trials to validate the potential of HRProfiler as a routine predictive and/or prognostic HRD biomarker to guide clinical decision-making.Significance:HRProfiler is a machine learning approach that reliably identifies homologous recombination deficiency in whole-exome–sequenced breast and ovarian cancers, outperforming other tools and providing clinically useful insights.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.See related commentary by Lim and Ju, p. 2348

2 March 2026
Verified
Other
Open access
PDF file
WZWei Zhao
Wei Zhao
TZTongwu Zhang
Tongwu Zhang
XHXing Hua
Xing Hua
PHPhuc Huu Hoang
Phuc Huu Hoang
MMMona Miraftab
Mona Miraftab
MLMaria Teresa Landi
Maria Teresa Landi
Supplementary Figure S8 shows chi squared tests and p values of clear cell features across the NS-LUAD expression subtypes.

2 March 2026
Verified
Other
Open access
PDF file
WZWei Zhao
Wei Zhao
TZTongwu Zhang
Tongwu Zhang
XHXing Hua
Xing Hua
PHPhuc Huu Hoang
Phuc Huu Hoang
MMMona Miraftab
Mona Miraftab
MLMaria Teresa Landi
Maria Teresa Landi
Supplementary Figure S5 shows analyses related to the steady subtype: enrichment plots of top gene sets associated with (A) cell cycle and (B) stemness, (C) violin plots showing expression levels of the proliferation marker MKI67, and (D) enrichment plots of top gene sets related to alveolar cells. (E) Enrichment plot of the top gene set associated with proliferative related to proliferation. F-G, Enrichment plots of top gene sets associated with chaotic related to (F) EMT, (G) fibroblasts. H-I, Violin plots depict expression levels of the mesenchymal markers (H) CDH2 and (I) TWIST1. The normalized enrichment scores (NES), p-values, and FDRs are indicated in the enrichment plots. Mean values are indicated by the yellow lines in the violin plots. P-values from two-sided Mann-Whitney U-test are shown in corresponding figures.